网红黑料

Investigator

Eric I Jeng

The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH [previously known as nonalcoholic steatohepatitis, NASH]).

Investigator

Ginger Clark

Ages

18 Years - 75 Years

Sexes

All

To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).

Ages

21 Years - 75 Years

Sexes

All